MP09-12 a prospective multicenter clinical trial for efficacy of mobile uroflowmetry in treatment-naïve benign prostatic hyperplasia undergoing medical therapy: interim results
Abstract
with older patients over 70 years showing good compliance and satisfaction to application-based measurements. CONCLUSIONS: Application-based UFM measurements well represent treatment response in patients with BPH undergoing medical therapy with good correlation of proudP (cid:1) measurements to in-patient UFM parameters. This technology may have a crucial role in the era of telemedicine, allowing accurate surveillance of BPH patients with extended follow-periods without necessitating frequent visits to the outpatient clinic.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.